胆固醇吸收抑制剂与高剂量阿托伐他汀联合治疗血脂控制不佳老年人冠心病疗效探讨  

Clinical effects investigation of cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling

作　　者：杨华俊 金丽华[2] 

机构地区：[1]杭州市富阳区第一人民医院药剂科,浙江省杭州311400 [2] 杭州市江干区人民医院药剂科

出　　处：《中国基层医药》2015年第17期2653-2656,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的：探讨胆固醇吸收抑制剂与高剂量阿托伐他汀联用于血脂控制不佳老年冠心病患者的临床效果及安全性差异。方法选取血脂控制不佳老年冠心病患者共240例，以随机抽样方法分为三组，即A组（80例）、B组（80例）即C组（80例），分别采用阿托伐他汀常规剂量，阿托伐他汀高剂量及阿托伐他汀高剂量＋胆固醇吸收抑制依折麦布治疗，比较三组总胆固醇（TC ）、低密度脂蛋白胆固醇（LDL-C ）达标率，治疗前后血脂指标及不良反应发生率等。结果 A、B 及 C 组 TC 达标率分别为40．00％（32／80）、62．50％（50／80）、96．25％（77／80）；A、B 及 C 组 LDL-C 达标率分别为51．25％（41／80）、81．25％（65／80）、98．75％（79／80）；C组TC和LDL-C达标率显著优于A、B组，差异有统计学意义（χ2＝58．28、27．83、48．13、13．61，均P＜0．05）；A组治疗后TC、TG、LDL-C及HDL-C分别为（5．35±1．26）mmol／L、（2．10±0．83）mmol／L、（2．85±0．93）mmol／L、（1．23±0．67）mmol／L；B 组治疗后 TC、TG、LDL-C 及 HDL-C 分别为（4．97±1．02）mmol／L，（2.05±0．81）mmol／L，（2．47±0．86）mmol／L，（1．20±0．65）mmol／L；C组治疗后TC、TG、LDL-C及HDL-C分别为（3．84±0．82）mmol／L、（1．74±0．56）mmol／L、（2．06±0．71）mmol／L、（1．24±0．52）mmol／L；C组治疗后TC、TG及LDL-C水平均显著优于A、B组，差异均有统计学意义（F＝3．80、4．94、4．21，均P＜0．05）；但三组治疗后HDL-C水平差异无统计学意义（P＞0．05）；A、B及C组不良反应发生率分别为1．25％（1／80）、3．75％（3／80）、2．50％（2／80），三组不良反应发生率差异无统计学意义（χ2＝1．03，P＜0．05）。结论胆固醇吸收抑制剂与高剂量阿托伐他汀联用于血脂控制不佳老年冠心病患者可有效控制血脂水平，提高血脂达标率，且�Objective To investigate clinical effects and safety difference of cholesterol absorption inhibitor associated with atorvastatin for high dose on elderly patients with coronary heart disease and poor lipid controlling. Methods 240 elderly patients with coronary heart disease and poor lipid controlling were chosen and randomly divided into 3 groups including group A （80 patients）with atorvastatin for conventional dose,group B （80 patients）with atorvastatin for high dose and group C （80 patients）with atorvastatin for high dose associated with ezetimibe for＆amp;nbsp;cholesterol absorption inhibitor;and the compliance rate of total cholesterol （TC）and low density lipoprotein cholesterol （LDL-C）,serum lipids before and after treatment and the incidence of adverse reaction of 3 groups were compared. Results The compliance rate of TC of group A,group B and group C were separately 40.00%（32/80）,62.50%（50/80）and 96.25%（77/80）;the compliance rate of LDL-C of group A,group B and group C were separately 51.25%（41/80）,81.25%（65/80）and 98.75%（79/80）;the compliance rate of TC and LDL-C of group C was significant better than that of group A and group B （χ2 =58.28,27.83,48.13,13.61,all P＆lt;0.05）.The levels of TC,TG,LDL-C and HDL-C of group A after treatment were separately （5.35 ±1.26）mmol/L,（2.10 ±0.83） mmol/L,（2.85 ±0.93）mmol/L and （1.23 ±0.67）mmol/L;the levels of TC,TG,LDL-C and HDL-C of group B after treatment were separately （4.97 ±1.02）mmol/L,（2.05 ±0.81）mmol/L,（2.47 ±0.86）mmol/L and （1.20 ± 0.65）mmol/L;the levels of TC,TG,LDL -C and HDL -C of C group after treatment were separately （3.84 ± 0.82）mmol/L,（1.74 ±0.56）mmol/L,（2.06 ±0.71）mmol/L and （1.24 ±0.52）mmol/L.The levels of TC,TG and LDL-C of group C after treatment was significant better than group A and group B （F=3.80,4.94,4.21,all P〉0.05）.There was no significant difference in level of HDL-C among 3 groups after treatment（P〈0.05）.The incidences

关 键 词：依折麦布 阿托伐他汀 老年人 冠心病 血脂 

分 类 号：R541.4[医药卫生—心血管疾病]